logo-loader
RNS
viewAstraZeneca

AstraZeneca divests rights for Losec to Cheplaphar

/**/ em{letter-spacing:.5pt;border:none windowtext 1.0pt;padding:0cm;font-weight:bold;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: purple } .au{size:21.0cm 842.0pt;margin:3.0cm 72.0pt 0cm 72.0pt;}div.au{}p.cn{margin:0cm;margin-bottom:.0001pt;line-height:120%;text-autospace:none;font-size:11.0pt;font-family:"Arial","sans-serif";color:black;font-weight:bold;line-height:normal}span.cl{font-weight:normal}p.co{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";font-weight: bold; line-height: 115%; text-align: center}span.cj{font-size:12.0pt;line-height:115%}p.cp{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";font-weight: bold; line-height: 115%}span.ch{font-size:12.0pt; line-height:115%}p.cq{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";font-div: italic; font-weight: bold; line-height: 115%; text-align: center}p.cr{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";line-height:115%} span.ce{line-height:115%}p.cs{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";text-align:justify;line-height:115%}p.ct{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";font-div: italic; line-height: 115%; text-align: justify}span.ca{letter-spacing:.25pt}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";}span.bz{color:#3C4242}span.by{line-height: 115%}p.cu{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";text-align:justify}span.bw{color:red}p.cv{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";font-weight: bold; line-height: 115%; text-align: justify} span.bu{color:black}span.bt{line-height:115%;color:black}span.bs{color: blue; line-height: 115%; text-decoration: underline}table.cw{width:451.35pt;margin-left:-5.4pt;border-collapse:collapse}tr.bl{height:21.15pt}td.bp{width:32.98%;padding:0cm 5.4pt 0cm 5.4pt;height:21.15pt}p.cx{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";font-weight: bold; line-height: 115%; page-break-after: avoid; text-align: justify; text-indent: -5.5pt}span.br{font-size:10.0pt;line-height: 115%}td.bn{width:45.16%;padding:0cm 5.4pt 0cm 5.4pt;height:21.15pt}span.bo{font-size:10.0pt;line-height:115%} td.bm{width:21.86%;padding:0cm 5.4pt 0cm 5.4pt;height:21.15pt}tr.bg{height:19.85pt}td.bj{width:32.98%;padding:0cm 5.4pt 0cm 5.4pt; height:19.85pt}p.cy{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";text-align:justify;text-indent:-5.5pt;line-height: 115%}td.bi{width:45.16%;padding:0cm 5.4pt 0cm 5.4pt; height:19.85pt}td.bh{width:21.86%;padding:0cm 5.4pt 0cm 5.4pt; height:19.85pt}td.bf{width:32.98%;padding:0cm 5.4pt 0cm 5.4pt;height:19.85pt}td.be{width:45.16%;padding:0cm 5.4pt 0cm 5.4pt;height:19.85pt}td.bd{width:21.86%;padding:0cm 5.4pt 0cm 5.4pt;height:19.85pt}span.bc{font-size:10.0pt;line-height:115%;color:black} td.bb{width:32.98%;padding:0cm 5.4pt 0cm 5.4pt; height:19.85pt}td.ba{width:45.16%;padding:0cm 5.4pt 0cm 5.4pt; height:19.85pt}td.az{width:21.86%;padding:0cm 5.4pt 0cm 5.4pt; height:19.85pt}p.cz{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";text-align:justify;text-indent:-5.5pt;line-height: 115%;}p.da{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";text-align:justify;line-height:115%;text-autospace: none;vertical-align:middle}span.aw{font-size:10.0pt; line-height:115%} /**/
RNS Number : 2876O
AstraZeneca PLC
01 October 2019
 

01 October 2019 07:05 BST

 

AstraZeneca divests rights for Losec to Cheplapharm

 

Agreement supports AstraZeneca's focus on three main therapy areas

 

AstraZeneca has agreed to sell the global commercial rights, excluding China, Japan, the US and Mexico, for Losec (omeprazole) and associated brands to Cheplapharm Arzneimittel GmbH (Cheplapharm).

 

The divestment includes medicines containing omeprazole marketed by AstraZeneca or its collaborators under the Acimax, Antra, Mepral, Mopral, Omepral and Zoltum medicine names.

 

Ruud Dobber, Executive Vice President, BioPharmaceuticals, said: "This agreement forms part of our strategy of reducing the portfolio of mature medicines to enable reinvestment in our main therapy areas, accelerating the number of innovative new medicines for patients with high unmet medical need. We already have an excellent relationship with Cheplapharm, and their strong European presence and global distribution network will help ensure continued patient access to Losec."

 

AstraZeneca will continue to manufacture and supply Losec and its associated medicines and commercialise the medicine in markets where it still holds the rights.

 

Financial considerations 

Cheplapharm will pay AstraZeneca approximately $243 million on completion of the agreement, plus sales-contingent milestones of up to $33 million in 2021 and 2022. Income arising from the upfront payment will be reported in the Company's financial statements in 2019 as Other Operating Income. In 2018, Losec sales in the countries covered by this agreement were $98 million, the majority of which were in Emerging Markets. The agreement does not change the Company's financial guidance for 2019. As there were no closing considerations to the transaction, the agreement became effective upon signing.

 

About Losec 

Losec is a proton pump inhibitor discovered and developed by AstraZeneca, which helps to reduce the amount of acid produced by the stomach in patients with gastrointestinal reflux conditions and ulcers. It has a number of approved indications and is commonly prescribed for patients with gastro oesophageal reflux disease.

 

The commercial rights to Losec and other omeprazole medicines in the US, Japan and Mexico, as well as the commercial rights to the over-the-counter version in France, Finland, Ireland, New Zealand and the Netherlands were previously divested.

 

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism (CVRM), and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow us on Twitter @AstraZeneca.

 

 

Media Relations

 

 

Gonzalo Viña

 

+44 203 749 5916

Rob Skelding

Oncology

+44 203 749 5821

Rebecca Einhorn

Oncology

+1 301 518 4122

Matt Kent

BioPharmaceuticals

+44 203 749 5906

Jennifer Hursit

Other

+44 203 749 5762

Christina Malmberg Hägerstrand

Sweden

+46 8 552 53 106

Michele Meixell

US

+1 302 885 2677

 

 

 

Investor Relations

 

 

Thomas Kudsk Larsen

 

+44 203 749 5712

Henry Wheeler

Oncology

+44 203 749 5797

Christer Gruvris

BioPharmaceuticals (CV, metabolism)

+44 203 749 5711

Nick Stone

BioPharmaceuticals (respiratory, renal)

+44 203 749 5716

Josie Afolabi

Other medicines

+44 203 749 5631

Craig Marks

Finance, fixed income

+44 7881 615 764

Jennifer Kretzmann

Corporate access, retail investors

+44 203 749 5824

US toll-free

 

+1 866 381 72 77


Adrian Kemp
Company Secretary
AstraZeneca PLC


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCEFLBBKBFFFBK

Quick facts: AstraZeneca

Price: 7503

Market: LSE
Market Cap: £98.43 billion
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE